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INTRODUCTION
Approximately 40% of patients with chronic urticaria (CU) 
have functional autoantibodies against FcεRIa or IgE on mast 
cells and basophils.
1 The same antibodies play a role in the 
pathogenesis of urticarial vasculitis (UV),
2 a subtype of CU (2%-
20% of cases) that is more common in women (60%-80%).
3
Antihistamines and systemic steroids are the most common 
drugs used in the treatment of CU, but the response to therapy 
is often incomplete.
4 In patients with UV or antihistamine-re-
sistant or steroid-dependent CU, immunomodulators such as 
cyclosporin A, sulfasalazine, and hydroxychloroquine have 
been shown to be effective in randomized controlled trials.
3 
However, there are concerns regarding the safety of these alter-
native treatment regimens.
In a few studies, plasmapheresis has been performed as an al-
ternative therapy to remove excessive circulating autoantibod-
ies in patients with CU or UV who do not respond to the above-
mentioned treatments.
5-7
This report describes a 35-year-old woman with UV who was 
treated successfully with plasmapheresis.
CASE REPORT
A 35-year-old woman presented with a 9-year history of recur-
rent episodes of generalized painful urticarial plaques associat-
ed with swelling of parts of her body. The urticarial plaques were 
accompanied by a burning sensation, rather than itching, and 
resolved gradually over 2-3 days without residual hyperpigmen-
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tation. There was no history of food or drug allergies. The pa-
tient had no complaints of arthralgias, abdominal pain, or fever.
The physical examination revealed multiple urticarial plaques 
distributed over her entire body, particularly the extremities, 
palms, and soles. The patient’s quality of life had declined be-
cause of the unpleasant appearance and frequency of the le-
sions.
The initial laboratory studies were within the normal range, 
including a complete blood count, thyroid function tests, thy-
roid autoantibodies, erythrocyte sedimentation rate, hepatitis 
markers, liver and renal function tests, urinalysis, stool analysis 
for parasite ova, total IgE, C3, C4, C1q, CH50, and C1 inhibitor 
levels, and antinuclear antibodies.
Skin prick testing was negative for foods commonly consumed 
in Turkey, including egg whites, egg yolks, cow’s milk, walnuts, 
peanuts, hazelnuts, almonds, sesame, lemons, tuna fish, mixed 
fish, beef, chicken meat, celery, beans, spinach, tomatoes, pota-
toes, green peas, soybeans, mushrooms, oranges, apples, peach-
es, apricots, and seven mixed cereals (Stallergènes; Antony, 
France).
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Immune complexes are found in the circulation of 30%-75% of patients with urticarial vasculitis and much evidence supports the role of these im-
mune complexes in the pathogenesis of urticarial vasculitis. Plasmapheresis is effective for removing these immune complexes; however, there are 
few reports on the use of plasmapheresis in the treatment of urticarial vasculitis. We describe a case of “refractory” urticarial vasculitis in which the 
symptoms improved after plasmapheresis treatment. We suggest that plasmapheresis be considered as an option in patients with severe or treat-
ment-resistant urticarial vasculitis.
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To obtain further information on the nature of her CU, we per-
formed an autologous serum skin test (ASST), which was posi-
tive. This result suggested an autoimmune basis for the condi-
tion. A biopsy from an affected area of skin showed perivascu-
lar lymphocyte and neutrophil infiltration and extravasation of 
erythrocytes in the superficial dermis typical of UV. Direct im-
munofluorescence revealed IgM, IgG, IgA, C3, and fibrinogen 
deposits on the superficial dermal blood vessels. Based on the 
biopsy results, the patient was diagnosed with UV.
Treatment with different elimination diets, H1/H2-antihista-
mines in standard and increased dosages, and oral corticoste-
roids (1 mg/kg/day) was unsuccessful; therefore, hydroxychlo-
roquine 400 mg/day was added to the treatment regimen. The 
hydroxychloroquine had to be stopped after 2 months due to 
the development of keratopathy. At this point, the patient was 
regarded as having “refractory” UV and plasmapheresis was 
considered.
The patient underwent two plasma exchanges 6 months apart, 
using 5% albumin as replacement fluid. One plasma volume 
was processed in each session. The procedure was performed 
with a Fresenius Cell Separator (ASTEC 204; Fresenius Kabi). 
The plasmapheresis procedures were completed without any 
adverse events.
Thirteen months after the plasmapheresis, the urticarial 
plaques reappeared, but the severity and duration of symptoms 
were lower than before the plasmapheresis. The new lesions 
were treated with oral desloratadine 5 mg/day for 5 days.
DISCUSSION
The cutaneous lesions of UV resemble urticaria; these lesions 
are composed of painful or nonpruritic urticarial plaques that 
typically persist for more than 24 hours.
3 UV can be associated 
with normal or low complement levels and usually resolves with 
hyperpigmentation.
3 UV may be local or systemic, and angio-
edema and arthritis are other clinical manifestations. The typi-
cal histological findings are essential for the diagnosis of UV. 
Immunofluorescent studies show granular deposits of immu-
noglobulins, fibrin, and complement.
3
Approximately 40%-50% of patients with CU have functional 
IgG autoantibodies against either the high-affinity IgE receptor 
(FcεRIa) or IgE, as revealed by positive ASST responses. These 
autoantibodies and immune complexes have also been found 
in the circulation of patients with UV.
2 Jones et al.
8 demonstrat-
ed the role of immune complexes in UV.
The treatment of these patients is often difficult. Antihista-
mines are used for symptomatic treatment, but are ineffective 
for controlling inflammation. Therefore, antihistamines cannot 
alter the disease prognosis.
2 Additional treatments with immu-
nomodulators such as cyclosporin A, sulfasalazine, and hy-
droxychloroquine are most commonly used to alter the course 
of the disease and to reduce the dosage of corticosteroids re-
quired.
2 However, there are concerns regarding the safety of 
these treatment options. Our patient refused treatment with a 
second immunosuppressive drug after developing keratopathy.
Alternative treatment modalities for the therapy of patients 
with UV include plasmapheresis or therapeutic plasma ex-
change. Plasmapheresis removes a variety of proteins from 
plasma, including antibodies, immune complexes, parapro-
teins, inflammatory mediators, drugs, toxins, and other plasma 
constituents. Plasmapheresis may have immunomodulatory 
effects via several mechanisms. The patient’s plasma is re-
placed with other colloids, such as albumin or allogeneic plas-
ma. In addition, plasma is separated by filtration or centrifuga-
tion and the remaining blood cells are returned to the patient in 
the replacement fluid. However, plasmapheresis should not be 
considered innocuous. The many complications of plasmapher-
esis include hypotension, respiratory distress, fluid-electrolyte 
abnormalities, allergic reactions, coagulation abnormalities, in-
fection, and even death.
9,10
In addition to removing the pathogenic plasma components 
directly, plasma exchange may also affect the immune system 
by enhancing the function of the reticuloendothelial system, re-
moving blocking antibodies, and making lymphocytes more 
vulnerable to immunosuppressive drugs. Furthermore, plasma 
exchange has been shown to improve T-cell-suppressor func-
tion.
11
There are reports on the beneficial effects of plasmapheresis 
in the treatment of CU and UV.
5-7 Plasmapheresis allows for the 
temporary resolution of the urticarial lesions by transiently re-
moving the circulating immune complexes. It has no effect on 
the production of new autoantibodies. Therefore, as Jiang et al.
6 
emphasized, plasmapheresis treatment is an “auxiliary” treat-
ment option in a patient with UV.
In conclusion, this case report supports the usability of plas-
mapheresis in patients with “refractory” UV. Further clinical 
studies are needed to confirm our experience.
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